The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CRSP | +41% | -27.03% | -6.1% | +380% |
| S&P | +16.9% | +95.99% | +14.39% | +217% |
CRISPR Therapeutics is a biotech company using gene therapy to try to correct genetic mutations to treat and cure diseases.
These companies' market-beating fuel hasn't run out yet.
CRISPR Therapeutics is a promising mid-cap biotech stock with an approved product in its portfolio.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.89M | 72.5% |
| Gross Profit | -$48.86M | 13.5% |
| Gross Margin | -5477.69% | 5442.8% |
| Market Cap | $4.20B | -8.4% |
| Market Cap / Employee | $10.69M | 0.0% |
| Employees | 393 | -3.4% |
| Net Income | -$208.55M | -65.0% |
| EBITDA | -$128.47M | 12.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $197.13M | -59.3% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $197.43M | -8.1% |
| Short Term Debt | $18.03M | 9.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -21.41% | -9.7% |
| Return On Invested Capital | -12.24% | -4.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$114.00M | -18.4% |
| Operating Free Cash Flow | -$113.88M | -19.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.07 | 1.73 | 1.51 | 2.30 | 4.44% |
| Price to Sales | 19.74 | 90.15 | 77.62 | 111.30 | 390.75% |
| Price to Tangible Book Value | 2.07 | 1.73 | 1.51 | 2.30 | 4.44% |
| Enterprise Value to EBITDA | -21.80 | -28.18 | -8.94 | -21.22 | 10.31% |
| Return on Equity | -13.1% | -19.2% | -19.7% | -25.3% | 80.99% |
| Total Debt | $227.55M | $223.69M | $219.36M | $215.45M | -6.85% |
An investor's look.
What investors need to know.
Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.
What will this mean for healthcare and for the future of society?
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
